Journals / Acta Medica Alanya / 2020 / Cilt: 4 - Sayı: 3

General approach to diabetic neuropathy

Diyabetik Nöropatiye Genel Yaklaşım

Pages
296–308
Publication Date
2022-09-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we aimed to comprehensively address the general approach to diabetic neuropathy, diagnosis and treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic neuropathy is the most common complication of diabetes mellitus.
📊
Key Findings & Data:It is estimated that there will be 578 million people diagnosed with DM in the world in 2030.
💡
Conclusion & Impact:In this review, we aimed to comprehensively address the general approach to diabetic neuropathy, diagnosis and treatment.
🔬Design:Review & Systematic Survey
📍Scope:2030 Verileri
⚙️Variables:Domain Parameters

Abstract

Diabetic neuropathy is the most common complication of diabetes mellitus. It causes microvascular and macrovascular damage and diagnosis can easily be overlooked by most physicians. Generally, the diagnosis of DN can be omitted by physicians dealing with diabetes treatment since it starts with non-specific findings, shows slow progression and can be confused with complaints in many diseases. It is estimated that there will be 578 million people diagnosed with DM in the world in 2030. Chronic hyperglycemia, microvascular insufficiency, oxidative and nitrosative stress, impaired neurotropism and autoimmunity are some of the factors that cause nerve destruction. Paresthesias such as tingling, burning, electrical shock-like sensations, numbness, throbbing, compression, pinpricks to the skin, complaints are the most common symptoms. There is no treatment for pathogenetic mechanisms in diabetic neuropathy that eliminates neuronal damage. The purposes of treatment are slowing down the progression of the disease, controlling the pain, preventing complications, quick and adequate treatment of occurred complications, maintaining the functional capacity of the patient. In this review, we aimed to comprehensively address the general approach to diabetic neuropathy, diagnosis and treatment.

Özet

Diyabetik nöropati (DN), diabetes mellitusun en yaygın komplikasyonudur. Mikro ve makrovasküler hasara neden olur ve çoğu hekim tanıyı kolaylıkla gözden kaçırabilir. Genel olarak; DN tanısı, spesifik olmayan bulgularla başladığı, yavaş ilerleme gösterdiği ve birçok hastalığa ait şikayetlerle karışabileceği için diyabet tedavisi ile uğraşan hekimler tarafından ihmal edilebilir. 2030 yılında dünyada 578 milyon kişinin DM tanısı alacağı tahmin edilmektedir. Kronik hiperglisemi, mikrovasküler yetmezlik, oksidatif ve nitrozatif stres, bozulmuş nörotropizm ve otoimmünite sinir harabiyetine neden olan faktörlerden bazılarıdır. Karıncalanma, yanma, elektrik çarpması benzeri hisler, uyuşma, zonklama, bası, deriye iğne batması gibi parestezik yakınmalar en sık görülen semptomlardır. Diyabetik nöropatide nöronal hasarı tamamen ortadan kaldıran patogenetik mekanizmaların tedavisi yoktur. Tedavinin amacı hastalığın ilerlemesini yavaşlatmak, ağrıyı kontrol altına almak, komplikasyonları önlemek, oluşan komplikasyonların hızlı ve yeterli tedavisi ve hastanın fonksiyonel kapasitesini korumaktır. Bu derlemede, diyabetik nöropati, tanı ve tedaviye genel yaklaşımı kapsamlı bir şekilde ele almayı amaçladık.

🔖

Cite This Article

Uzuner, B., Ketenci, S., Salbaş, E. (2022). General approach to diabetic neuropathy. Acta Medica Alanya, Cilt: 4 - Sayı: 3, 296–308. https://ajindex.com/articles/425798

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. C.C. Robinson, R.P.G. Barreto, R.D.M. Plentz, Effects of whole body vibration in individuals with diabetic peripheral neuropathy: a systematic review, J Musculoskelet Neuronal Interact 18(3) (2018) 382-388.
  2. J.L. Harding, M.E. Pavkov, E.W. Gregg, et al., Trends of Nontraumatic Lower-Extremity Amputation in End-Stage Renal Disease and Diabetes: United States, 2000- 2015, Diabetes Care 42(8) (2019) 1430-1435.
  3. C. Perez, M. Latymer, M. Almas, et al., Does Duration of Neuropathic Pain Impact the Effectiveness of Pregabalin?, Pain Pract 17(4) (2017) 470-479. https://doi. org/10.1111/papr.12469 4. A.I. Vinik, M.L. Nevoret, C. Casellini, et al., Diabetic neuropathy, Endocrinol Metab Clin North Am 42(4) (2013) 747-87.
  4. R. Hasan, B. Firwana, T. Elraiyah, et al., A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome, J Vasc Surg 63(2 Suppl) (2016) 22S-28S e1-2.
  5. E.J. Barrett, Z. Liu, M. Khamaisi, et al., Diabetic Microvascular Disease: An Endocrine Society Scientific Statement, J Clin Endocrinol Metab 102(12) (2017) 4343- 4410.
  6. V.L. Fisher, A.A. Tahrani, Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives, Diabetes Metab Syndr Obes 10 (2017) 419-434.
  7. P. Saeedi, I. Petersohn, P. Salpea, et al., Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition, Diabetes Res Clin Pract 157 (2019) 107843.
  8. I. Satman, T. Yilmaz, A. Sengul, et al., Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP), Diabetes Care 25(9) (2002) 1551-6.
  9. T. Erbas, M. Ertas, A. Yucel, et al., Prevalence of peripheral neuropathy and painful peripheral neuropathy in Turkish diabetic patients, J Clin Neurophysiol 28(1) (2011) 51-5.
  10. P.K. Thomas, Classification, differential diagnosis, and staging of diabetic peripheral neuropathy, Diabetes 46 Suppl 2 (1997) S54-7. https://doi.org/10.2337/ diab.46.2.s54 12. M. Kazamel, P.J. Dyck, Sensory manif